drugset
drugset / Trial / NCT05440136

A Safety Study of LY3462817 in Healthy Japanese and Non-Japanese Participants

NCT05440136 ↗

Phase 1 Completed 33 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3462817 in healthy Japanese and non-Japanese participants. The study will also assess how fast LY3462817 gets into the blood stream and how long it takes the body to remove it. The study is open to healthy participants. The study will last up to approximately 12 weeks.

Timeline

Start
2022-06-28
Primary completion
2023-03-08
Completion
2023-03-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Peresolimab Monoclonal antibody — Subcutaneous

Indications

No indication recorded.